Aurora M. Fontainhas

Array ( [id] => 14504475 [patent_doc_number] => 20190195892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => METHOD OF DISTINGUISHING BETWEEN DIFFERENT NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 16/121481 [patent_app_country] => US [patent_app_date] => 2018-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16121481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807843 [patent_doc_number] => 20210130396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => METHOD FOR PURIFYING PROTEINS [patent_app_type] => utility [patent_app_number] => 16/640073 [patent_app_country] => US [patent_app_date] => 2018-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16640073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986515 [patent_doc_number] => 20190062415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => ANTIBODIES RECOGNIZING ALPHA-SYNUCLEIN [patent_app_type] => utility [patent_app_number] => 16/107949 [patent_app_country] => US [patent_app_date] => 2018-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16107949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452595 [patent_doc_number] => 20200362021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => ANTI-APELIN ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/639808 [patent_app_country] => US [patent_app_date] => 2018-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493249 [patent_doc_number] => 20200046813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals [patent_app_type] => utility [patent_app_number] => 16/102134 [patent_app_country] => US [patent_app_date] => 2018-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16102134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17044940 [patent_doc_number] => 11098108 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => Antibody binding active alpha-synuclein [patent_app_type] => utility [patent_app_number] => 16/635943 [patent_app_country] => US [patent_app_date] => 2018-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 27 [patent_no_of_words] => 19942 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16635943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13990061 [patent_doc_number] => 20190064188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => MICRO-RNA, AUTOANTIBODY AND PROTEIN MARKERS FOR DIAGNOSIS OF NEURONAL INJURY [patent_app_type] => utility [patent_app_number] => 16/052512 [patent_app_country] => US [patent_app_date] => 2018-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16052512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13586515 [patent_doc_number] => 20180344806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals [patent_app_type] => utility [patent_app_number] => 16/046448 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29664 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16046448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13549347 [patent_doc_number] => 20180326221 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => SYSTEM FOR OPTICAL STIMULATION OF TARGET CELLS [patent_app_type] => utility [patent_app_number] => 16/041647 [patent_app_country] => US [patent_app_date] => 2018-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16041647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18505701 [patent_doc_number] => 11703511 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-18 [patent_title] => Anti-isoAsp7 amyloid b (Ab) antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/632289 [patent_app_country] => US [patent_app_date] => 2018-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 20 [patent_no_of_words] => 18044 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16632289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15880487 [patent_doc_number] => 10646568 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-12 [patent_title] => Targeting immunotherapy for amyloidosis [patent_app_type] => utility [patent_app_number] => 16/036900 [patent_app_country] => US [patent_app_date] => 2018-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 105 [patent_no_of_words] => 31383 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16036900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793399 [patent_doc_number] => 20190010238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => MONOCLONAL ANTIBODY TO TREAT ALZHEIMER'S DISEASE, PRION DISEASE, FRONTOTEMPORAL DEMENTIAS AND TRAUMATIC BRAIN INJURY/CHRONIC TRAUMATIC ENCEPHALOPATHY [patent_app_type] => utility [patent_app_number] => 16/031418 [patent_app_country] => US [patent_app_date] => 2018-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16126 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16031418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18413191 [patent_doc_number] => 11667724 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Anti-human CEACAM5 antibody Fab fragment [patent_app_type] => utility [patent_app_number] => 16/628975 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 16228 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 173 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16628975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13603899 [patent_doc_number] => 20180353498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => REDUCING MEMORY LOSS IN MAMMALS SUFFERING FROM ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 16/026934 [patent_app_country] => US [patent_app_date] => 2018-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10509 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16026934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14375267 [patent_doc_number] => 20190161546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => SP35 Antibodies And Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/018819 [patent_app_country] => US [patent_app_date] => 2018-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16018819 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931153 [patent_doc_number] => 20200157210 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => FUSION PROTEIN [patent_app_type] => utility [patent_app_number] => 16/625278 [patent_app_country] => US [patent_app_date] => 2018-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18203 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16625278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15102233 [patent_doc_number] => 10472417 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => Human PAC1 antibodies [patent_app_type] => utility [patent_app_number] => 16/017891 [patent_app_country] => US [patent_app_date] => 2018-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 40385 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16017891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17043833 [patent_doc_number] => 11096993 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => Method of treating macular degeneration using botulinum toxin-based pharmaceuticals [patent_app_type] => utility [patent_app_number] => 16/015984 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 48 [patent_no_of_words] => 27802 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16015984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13490217 [patent_doc_number] => 20180296651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals [patent_app_type] => utility [patent_app_number] => 16/013552 [patent_app_country] => US [patent_app_date] => 2018-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16013552 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16320236 [patent_doc_number] => 10780183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => Messenger RNA therapy for the treatment of Friedreich's ataxia [patent_app_type] => utility [patent_app_number] => 16/012138 [patent_app_country] => US [patent_app_date] => 2018-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 21695 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16012138 [rel_patent_id] =>[rel_patent_doc_number] =>)